RT Journal Article
SR Electronic
T1 Alpharadin® in the treatment of skeletal metastasis secondary to metastatic prostate cancer: An educational exhibit
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1308
OP 1308
VO 54
IS supplement 2
A1 Duong, Eric
A1 Orquiza, Michael
A1 Khorjekar, Gauri
A1 Van Nostrand, Douglas
YR 2013
UL http://jnm.snmjournals.org/content/54/supplement_2/1308.abstract
AB 1308 Learning Objectives The objectives of this educational exhibit are to: 1. Describe what Alpharadin® is. 2. Discuss its mechanism of action. 3. List the advantages of Alpharadin®. 4. Review the results of initial trials. Alpharadin® is presently not approved for use by the Food and Drug Administration. Prostate cancer is one of the most prevalent cancers in the world, and frequently, prostate cancer may metastasize to the bone. In order to remove the stimulatory affects of testosterone on prostate metastases such as in bone, castration is an important management option. However, some patients may advance to a more serious phase called castration resistant prostate cancer (CRPC). Currently, the therapies that target CRPC bone metastases primarily help alleviate pain and do not improve overall survival (OS), and new treatment modalities are needed to treat this group of patients. One new treatment option under study for patients with CRPC bone metastases is Alpharadin®. As noted above, the objective of this educational exhibit is to present an overview of Alpharadin® in the treatment of CRPC bone metastases.